SG11201809625RA - 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer - Google Patents
1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancerInfo
- Publication number
- SG11201809625RA SG11201809625RA SG11201809625RA SG11201809625RA SG11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA SG 11201809625R A SG11201809625R A SG 11201809625RA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- company
- box
- indiana
- indianapolis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111111111111111111111111110111111111111111111111111111111011111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\"\"1 WO 2017/213919 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, C07D 405/06 (2006.01) A61P 35/00 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, A61K 31/4045 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (21) International Application Number: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, PCT/US2017/035097 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 31 May 2017 (31.05.2017) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/348,457 10 June 2016 (10.06.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (71) Applicant: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US). Declarations under Rule 4.17: (72) Inventors: BASTIAN, Jolie Anne; c/o ELI LILLY — as to applicant's entitlement to apply for and be granted a AND COMPANY, P.O. Box 6288, Indianapolis, Indi- patent (Rule 4.17(ii)) ana 46206-6288 (US). CHEN, Jiehao; c/o ELI LILLY — as to the applicant's entitlement to claim the priority of the — AND COMPANY, P.O. Box 6288, Indianapolis, Indiana earlier application (Rule 4.17(iii)) 46206-6288 (US). COHEN, Jeffrey Daniel; c/o ELI LIL- Published: LY AND COMPANY, P.O. Box 6288, Indianapolis, Indi- = — with international search report (Art. 21(3)) ana 46206-6288 (US). HENRY, James Robert; c/o ELI — with sequence listing part of description (Rule 5.2(a)) LILLY AND COMPANY, P.O. Box 6288, Indianapolis, In- _ diana 46206-6288 (US). MCMILLEN, William Thomas; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi- anaoplis, Indiana 46206-6288 (US). REAMAN, Bradley = Earl; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). RUBIO, Almude- na; c/o ELI LILLY AND COMPANY, P.O. Box 6288, In- — = — dianapolis, Indiana 46206-6288 (US). SALL, Daniel Jon; = — c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indi- anapolis, Indiana 46206-6288 (US). ZHAO, Gaiying; c/o ELI LILLY AND COMPANY, P.O. Box 6288, Indianapo- lis, Indiana 46206-6288 (US). = = Agent: TUCKER, Tina M. et al.; ELI LILLY AND COM- (74) _ PANY, P.O. Box 6288, Indianapolis, Indiana 46206-6288 = (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = 1-1 (54) Title: 1-TETRAHYDROPYRANYLCARBONYL-2,3-DIHYDRO-1H-INDOLE COMPOUNDS FOR TREATING CANCER 01 1-1 (57) : The present invention relates to certain novel 2,3-dihydro-1H-indole corn- 01 R2a pounds, pharmaceutical compositions comprising the compounds, and methods of using the M 1-1 Ric 0 R2 compounds to treat cancer, more particularly for the treatment of cancer selected from the Ri b IN 11 N 1 . I 11 1.1 group consisting of melanoma, acute myeloid leukemia, chronic lymphocytic leukemia, col- orectal cancer, breast cancer, lung cancer, ovarian cancer, fallopian tube carcinoma, primary R1 a N - R3 a peritoneal carcinoma, cervical cancer, gastric cancer, liver cancer, pancreatic cancer, thyroid ei 0 cancer, 0 glioblastoma, non- Hodgkin's lymphoma, and Hodgkin's lymphoma. C
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662348457P | 2016-06-10 | 2016-06-10 | |
| PCT/US2017/035097 WO2017213919A1 (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809625RA true SG11201809625RA (en) | 2018-11-29 |
Family
ID=59031409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809625RA SG11201809625RA (en) | 2016-06-10 | 2017-05-31 | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US10759786B2 (en) |
| EP (1) | EP3468965B1 (en) |
| JP (1) | JP6632746B2 (en) |
| KR (1) | KR102241258B1 (en) |
| CN (1) | CN109641881B (en) |
| AR (1) | AR108586A1 (en) |
| AU (1) | AU2017277833B2 (en) |
| BR (1) | BR112018072872A2 (en) |
| CA (1) | CA3027035C (en) |
| CL (1) | CL2018003543A1 (en) |
| CO (1) | CO2018013251A2 (en) |
| CR (1) | CR20180579A (en) |
| CY (1) | CY1123660T1 (en) |
| DK (1) | DK3468965T3 (en) |
| DO (1) | DOP2018000278A (en) |
| EA (1) | EA037419B1 (en) |
| EC (1) | ECSP19001734A (en) |
| ES (1) | ES2797981T3 (en) |
| HR (1) | HRP20200769T1 (en) |
| HU (1) | HUE050155T2 (en) |
| IL (1) | IL263497B (en) |
| JO (1) | JOP20170131B1 (en) |
| LT (1) | LT3468965T (en) |
| MA (1) | MA45224B1 (en) |
| MD (1) | MD3468965T2 (en) |
| ME (1) | ME03744B (en) |
| MX (1) | MX2018015275A (en) |
| MY (1) | MY197462A (en) |
| NZ (1) | NZ748500A (en) |
| PE (1) | PE20190378A1 (en) |
| PH (1) | PH12018502572A1 (en) |
| PL (1) | PL3468965T3 (en) |
| PT (1) | PT3468965T (en) |
| RS (1) | RS60322B1 (en) |
| SG (1) | SG11201809625RA (en) |
| SI (1) | SI3468965T1 (en) |
| TW (1) | TWI671294B (en) |
| UA (1) | UA122526C2 (en) |
| WO (1) | WO2017213919A1 (en) |
| ZA (1) | ZA201807688B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| CN109069488B (en) | 2016-03-07 | 2021-09-07 | 英安塔制药有限公司 | Hepatitis B antiviral agent |
| AU2018326474A1 (en) | 2017-08-28 | 2020-04-16 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US20210179607A1 (en) * | 2017-11-01 | 2021-06-17 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP3727374A4 (en) * | 2017-12-21 | 2021-11-10 | Merck Patent GmbH | Combination of an anti-pd-l1 antibody and ido1 inhibitor for the treatment of cancer |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US20210161896A1 (en) * | 2018-08-17 | 2021-06-03 | Merck Sharp & Dohme Corp. | Novel substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors |
| UY38383A (en) | 2018-09-21 | 2020-04-30 | Enanta Pharm Inc | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS |
| US20210403469A1 (en) * | 2018-11-06 | 2021-12-30 | Merck Sharp & Dohme Corp. | Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors |
| KR20210093951A (en) | 2018-11-21 | 2021-07-28 | 이난타 파마슈티칼스, 인코포레이티드 | Functionalized Heterocycles as Antiviral Agents |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11472808B2 (en) | 2019-06-04 | 2022-10-18 | Enanta Pharmaceuticals, Inc. | Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents |
| US11760755B2 (en) | 2019-06-04 | 2023-09-19 | Enanta Pharmaceuticals, Inc. | Hepatitis B antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2021055425A2 (en) | 2019-09-17 | 2021-03-25 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| US11802125B2 (en) | 2020-03-16 | 2023-10-31 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| CN114105961B (en) * | 2021-12-10 | 2023-09-12 | 海南梵圣生物科技有限公司 | Preparation method of IDO1 inhibitor (LY-3381916) |
| CN114213310B (en) * | 2021-12-31 | 2024-02-23 | 中国药科大学 | Indoline compound and derivative thereof, preparation method, pharmaceutical composition and application |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE482747T1 (en) * | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | NEW AMIDE DERIVATIVES AND THEIR PHARMACEUTICAL USES |
| CN101212967A (en) * | 2005-05-10 | 2008-07-02 | 因塞特公司 | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| CA2713519A1 (en) | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
| SI2824100T1 (en) * | 2008-07-08 | 2018-06-29 | Incyte Holdings Corporation | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| NO2694640T3 (en) * | 2011-04-15 | 2018-03-17 | ||
| SG11201506920QA (en) * | 2013-03-15 | 2015-09-29 | Bristol Myers Squibb Co | Ido inhibitors |
| DK3125883T3 (en) * | 2014-04-04 | 2020-10-19 | Iomet Pharma Ltd | CONTENTS DERIVATIVES FOR USE IN MEDICINE |
| AR102537A1 (en) * | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | IMMUNOMODULATING AGENTS |
| EP3405587A4 (en) * | 2015-12-23 | 2019-10-30 | Moonshot Pharma LLC | Methods for inducing an immune response by promoting premature termination codon read-through |
-
2017
- 2017-05-24 JO JOP/2017/0131A patent/JOP20170131B1/en active
- 2017-05-24 AR ARP170101413A patent/AR108586A1/en unknown
- 2017-05-25 TW TW106117300A patent/TWI671294B/en active
- 2017-05-31 MX MX2018015275A patent/MX2018015275A/en unknown
- 2017-05-31 US US16/307,612 patent/US10759786B2/en active Active
- 2017-05-31 DK DK17728990.7T patent/DK3468965T3/en active
- 2017-05-31 NZ NZ748500A patent/NZ748500A/en not_active IP Right Cessation
- 2017-05-31 CR CR20180579A patent/CR20180579A/en unknown
- 2017-05-31 RS RS20200623A patent/RS60322B1/en unknown
- 2017-05-31 MY MYPI2018002369A patent/MY197462A/en unknown
- 2017-05-31 UA UAA201811735A patent/UA122526C2/en unknown
- 2017-05-31 SG SG11201809625RA patent/SG11201809625RA/en unknown
- 2017-05-31 KR KR1020187035215A patent/KR102241258B1/en active IP Right Grant
- 2017-05-31 ME MEP-2020-98A patent/ME03744B/en unknown
- 2017-05-31 AU AU2017277833A patent/AU2017277833B2/en not_active Ceased
- 2017-05-31 EP EP17728990.7A patent/EP3468965B1/en active Active
- 2017-05-31 CA CA3027035A patent/CA3027035C/en active Active
- 2017-05-31 PT PT177289907T patent/PT3468965T/en unknown
- 2017-05-31 CN CN201780035976.4A patent/CN109641881B/en active Active
- 2017-05-31 MD MDE20190462T patent/MD3468965T2/en unknown
- 2017-05-31 WO PCT/US2017/035097 patent/WO2017213919A1/en unknown
- 2017-05-31 SI SI201730252T patent/SI3468965T1/en unknown
- 2017-05-31 MA MA45224A patent/MA45224B1/en unknown
- 2017-05-31 LT LTEP17728990.7T patent/LT3468965T/en unknown
- 2017-05-31 US US15/609,115 patent/US9872853B2/en active Active
- 2017-05-31 PL PL17728990T patent/PL3468965T3/en unknown
- 2017-05-31 BR BR112018072872-1A patent/BR112018072872A2/en not_active Application Discontinuation
- 2017-05-31 JP JP2018563823A patent/JP6632746B2/en active Active
- 2017-05-31 ES ES17728990T patent/ES2797981T3/en active Active
- 2017-05-31 HU HUE17728990A patent/HUE050155T2/en unknown
- 2017-05-31 EA EA201892479A patent/EA037419B1/en unknown
- 2017-05-31 PE PE2018003199A patent/PE20190378A1/en unknown
-
2018
- 2018-11-15 ZA ZA2018/07688A patent/ZA201807688B/en unknown
- 2018-12-04 IL IL263497A patent/IL263497B/en active IP Right Grant
- 2018-12-06 PH PH12018502572A patent/PH12018502572A1/en unknown
- 2018-12-06 CO CONC2018/0013251A patent/CO2018013251A2/en unknown
- 2018-12-10 DO DO2018000278A patent/DOP2018000278A/en unknown
- 2018-12-10 CL CL2018003543A patent/CL2018003543A1/en unknown
-
2019
- 2019-01-09 EC ECSENADI20191734A patent/ECSP19001734A/en unknown
-
2020
- 2020-05-12 HR HRP20200769TT patent/HRP20200769T1/en unknown
- 2020-06-05 CY CY20201100508T patent/CY1123660T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201908820VA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201808108XA (en) | Synthesis of indazoles | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
| SG11201803918VA (en) | Production of steviol glycosides in recombinant hosts | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201809560QA (en) | Enhancer of zeste homolog 2 inhibitors | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |